| Title |
Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants
|
|---|---|
| Published in |
PLOS ONE, November 2012
|
| DOI | 10.1371/journal.pone.0047725 |
| Pubmed ID | |
| Authors |
Francesc Vidal, Miguel López-Dupla, Montserrat Laguno, Sergi Veloso, Josep Mallolas, Javier Murillas, Carmen Cifuentes, Lluis Gallart, Teresa Auguet, Gloria Sampériz, Antoni Payeras, Pilar Hernandez, Mireia Arnedo, Josep Ma Gatell, Cristóbal Richart |
| Abstract |
This was a safety and efficacy pharmacogenetic study of a previously performed randomized trial which compared the effectiveness of treatment of hepatitis C virus infection with pegylated interferon alpha (pegIFNα) 2a vs. 2b, both with ribavirin, for 48 weeks, in HCV-HIV coinfected patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 82 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 4% |
| United Kingdom | 2 | 2% |
| Brazil | 1 | 1% |
| Spain | 1 | 1% |
| Colombia | 1 | 1% |
| Unknown | 74 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 20% |
| Student > Master | 13 | 16% |
| Researcher | 11 | 13% |
| Student > Bachelor | 9 | 11% |
| Student > Postgraduate | 6 | 7% |
| Other | 17 | 21% |
| Unknown | 10 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 33% |
| Agricultural and Biological Sciences | 15 | 18% |
| Psychology | 8 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Other | 7 | 9% |
| Unknown | 14 | 17% |